VAERS Explorer
Back to explore

Report #2893776

Received Apr 23, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Female
Age
1.3 yrs
State
PA
Recovered
Unknown
Vaccinated
Dec 4, 2025
Onset
Dec 4, 2025
Days to onset
0
Hospital days

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
DTAPIPVDTAP + IPV (QUADRACEL)SANOFI PASTEURUNKU8209CBLL

Symptoms (2)

No adverse eventProduct preparation issue

Symptom narrative

received only the powder HIB portion that was mixed incorrectly with a separate sterile diluent,with no reported adverse event; Initial information received on 02-Apr-2026 regarding an unsolicited valid non-serious case received from other or unknown health care professional (HCP). This case involves a 15-month-old female patient who received only the powder Haemophilus influenzae type b (HIB) portion that was mixed incorrectly with a separate sterile diluent, with no reported adverse event of acellular pertussis vaccine, diphtheria toxoid, poliomyelitis vaccine (inactivated), and tetanus toxoid (QUADRACEL). The patient's past medical history, past drugs, vaccination(s), family history, and concomitant medications were not provided. On 04-Dec-2025, the patient started taking acellular pertussis vaccine, diphtheria toxoid, poliomyelitis vaccine (inactivated), and tetanus toxoid Suspension for injection as 0.5 mL (route: unknown) for immunization. The patient received only the powder HIB portion that was mixed incorrectly with a separate sterile diluent, with no reported adverse event (Product preparation error), onset: 04-Dec-2025 and latency: same day) (batch: U8209CB, expiry date: unknown)]. Action taken: not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Medical history

Comments: NONE